Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4814906 | 0.82 | MEN1 (0.48) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL536304 | 0.82 | MEN1 (0.48) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL20335022 | 0.82 | MEN1 (0.48) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL30832481 | 0.82 | MEN1 (0.50) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL6515271 | 0.82 | MEN1 (0.50) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL630728 | 0.81 | MEN1 (0.47) | MEN1KMT2ANPSR1 | |
| SCHEMBL29603146 | 0.81 | — | — | |
| SCHEMBL317040 | 0.81 | MEN1 (0.47) | MEN1KMT2ANPSR1 | |
| SCHEMBL205894 | 0.81 | MEN1 (0.47) | MEN1KMT2ANPSR1 | |
| SCHEMBL7606324 | 0.81 | MEN1 (0.49) | MEN1KMT2ANPSR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143249-B2 | Prodrugs of A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110160162-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| EP-2301937-A1 | Prodrugs of A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100056538-A1 | Pro-drugs of A2B Adenosine Receptor Antagonists | GILEAD PALO ALTO, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7625881-B2 | Prodrugs of A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1891070-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006138376-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060293283-A1 | Prodrugs of A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160162-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | MEN1 3655/4885KMT2A 2662/4885NPSR1 173/4885 |
| US-20100056538-A1 | Pro-drugs of A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | MEN1 3154/4885KMT2A 3714/4885NPSR1 165/4885 |
| US-20060293283-A1 | Prodrugs of A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | MEN1 3655/4885KMT2A 2662/4885NPSR1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.